| Policy Title | Policy Number | Effective Date |
|---|
| Abatacept (Orencia) (PDF) | CP.PHAR.241 | July 1, 2025 |
| AbobotulinumtoxinA (Dysport) (PDF) | CP.PHAR.230 | October 1, 2025 |
| Acquired Brain Injury (Subacute and Chronic) Inpatient Neurorehabilitation (PDF) | AR.CP.MP.501 | October 1, 2025 |
| Ado-Trastuzumab (Kadcyla) (PDF) | CP.PHAR.229 | July 1, 2025 |
| Aducanumab (Aduhelm) (PDF) | CP.PHAR.468 | July 1, 2025 |
| Afamelanotide (Scenesse) (PDF) | CP.PHAR.444 | April 1, 2025 |
| Afamitresgene Autoleucel (Tecelra) (PDF) | CP.PHAR.678 | May 1, 2025 |
| Aflibercept (Eylea) (PDF) | CP.PHAR.184 | November 1, 2025 |
| Agalsidase beta (Fabrazyme) (PDF) | CP.PHAR.158 | September 1, 2025 |
| Air Ambulance (PDF) | CP.MP.175 | May 1, 2025 |
| Alemtuzumab (Lemtrada) (PDF) | CP.PHAR.243 | July 1, 2025 |
| Alglucosidase (Lumizyme) (PDF) | CP.PHAR.160 | April 1, 2025 |
| Allogeneic cultured keratinocytes and dermal fibroblasts (StrataGraft)(PDF) | CP.PHAR.562 | April 1, 2025 |
| Allogenic processed thymus tissue-agdc (Rethymic) (PDF) | CP.PHAR.563 | April 1, 2025 |
| Alpha1-Proteinase Inhibitors (Aralast NP, Glassia, Prolastin-C, Zemaira) (PDF) | CP.PHAR.94 | April 1, 2025 |
| Amisulpride (Barhemsys) (PDF) | CP.PMN.236 | October 1, 2025 |
| Amivantamab-vmjw (Rybrevant) (PDF) | CP.PHAR.544 | October 1, 2025 |
| Anifrolumab-fnia (Saphnelo) (PDF) | CP.PHAR.551 | March 1, 2025 |
| Anti-Inhibitor Coagulant Complex, Human (Feiba) (PDF) | CP.PHAR.217 | April 1, 2025 |
| Antithrombin III (ATryn, Thrombate III) (PDF) | CP.PHAR.564 | April 1, 2025 |
| Antithymocyte Globulin (Atgam, Thymoglobulin) (PDF) | CP.PHAR.506 | January 1, 2025 |
| Adzynma (ADAMTS13, recombinant-krhn) (PDF) | CP.PHAR.635 | April 1, 2025 |
| Applied Behavior Analysis (PDF) | CP.BH.104 | June 1, 2025 |
| Applied Behavioral Analysis Documentation Requirements (PDF) | CP.BH.105 | June 1, 2025 |
| Aprepitant (Aponvie, Emend, Cinvanti), Fosaprepitant (Emend for injection, Focinvez) (PDF) | CP.PMN.19 | October 1, 2025 |
| Asfotase Alfa (Strensiq) (PDF) | CP.PHAR.328 | December 1, 2022 |
| Assistive Reproductive Technology (PDF) | CP.MP.55 | July 1, 2025 |
| Atezolizumab (Tecentriq) (PDF) | CP.PHAR.235 | May 1, 2025 |
| Atidarsagene autotemcel (Lenmeldy) (PDF) | CP.PHAR.602 | August 1, 2025 |
| Avacincaptad pegol (Izervay) (PDF) | CP.PHAR.641 | May 1, 2025 |
| Avalglucosidase Alfa-ngpt (Nexviazyme) (PDF) | CP.PHAR.521 | April 1, 2025 |
| Avelumab (Bavencio) (PDF) | CP.PHAR.333 | April 1, 2025 |
| Axatilimab-csfr (Niktimvo) (PDF) | CP.PHAR.691 | Aril 1, 2025 |
| Axicabtagene Ciloleucel (Yescarta®) (PDF) | CP.PHAR.362 | June 1, 2025 |
| Azacitidine (Vidaza) (PDF) | CP.PHAR.387 | March 1, 2025 |
| Baclofen (Gablofen, Lioresal, Lyvispah, Ozobax) (PDF) | CP.PHAR.149 | January 1, 2025 |
| Bamlanivimab-etesevimab (LY-CoV555-LY-CoV016) (PDF) | CP.PHAR.532 | July 1, 2023 |
| Bariatric Surgery (PDF) | CP.MP.37 | June 1, 2025 |
| Behavioral Health Treatment Documentation Requirements (PDF) | CP.BH.500 | August 1, 2025 |
| Belantamab mafodotin (Blenrep) (PDF) | CP.PHAR.469 | July 1, 2025 |
| Belatacept (Nulojix) (PDF) | CP.PHAR.201 | January 1, 2025 |
| Belimumab (Benlysta) (PDF) | CP.PHAR.88 | October 1, 2025 |
| Belinostat (Beleodaq) (PDF) | CP.PHAR.311 | March 1, 2025 |
| Bendamustine (Bendeka, Treanda) (PDF) | CP.PHAR.307 | March 1, 2025 |
| Benralizumab (Fasenra) (PDF) | CP.PHAR.373 | April 1, 2025 |
| Beremagene geperpavec-svdt (Vyjuvek) (PDF) | CP.PHAR.592 | December 1, 2025 |
| Beremagene geperpavec-svdt (Vyjuvek) (PDF) | CP.PHAR.592 | Version effective until December 1, 2025 |
| Betibeglogene Autotemcel (Zynteglo) (PDF) | CP.PHAR.545 | December 1, 2025 |
| Betibeglogene Autotemcel (Zynteglo) (PDF) | CP.PHAR.545 | Version effective until December 1, 2025 |
| Bevacizumab (Avastin, Mvasi, Zirabev) (PDF) | CP.PHAR.93 | September 1, 2025 |
| Bezlotoxumab (Zinplava) (PDF) | CP.PHAR.300 | April 1, 2025 |
| Bimatoprost Implant (Durysta)(PDF) | CP.PHAR.486 | October 1, 2025 |
| Biofeedback (PDF) | CP.MP.168 | February 1, 2025 |
| Biofeedback for Behavioral Health Disorders (PDF) | CP.BH.300 | July 1, 2025 |
| Blinatumomab (Blincyto) (PDF) | CP.PHAR.312 | December 1, 2025 |
| Blinatumomab (Blincyto) (PDF) | CP.PHAR.312 | Version effective until December 1, 2025 |
| Bone-Anchored Hearing Aids (PDF) | AR.CP.MP.93 | July 16, 2025 |
| Bortezomib (Velcade) (PDF) | CP.PHAR.410 | April 1, 2025 |
| Bremelanotide (Vyleesi) (PDF) | CP.PHAR.434 | February 1, 2023 |
| Brentuximab Vedotin (Adcetris) (PDF) | CP.PHAR.303 | December 1, 2025 |
| Brentuximab Vedotin (Adcetris) (PDF) | CP.PHAR.303 | Version effective until December 1, 2025 |
| Brexanolone (Zulresso) (PDF) | CP.PHAR.417 | July 1, 2025 |
| Brexucabtagene Autoleucel (Tecartus) (PDF) | CP.PHAR.472 | April 1, 2025 |
| Brivaracetam (Briviact) (PDF) | CP.PMN.297 | January 1, 2025 |
| Brolucizumab-dbll (Beovu) (PDF) | CP.PHAR.445 | June 1, 2025 |
| Brolucizumab-dbll (Beovu) (PDF) | CP.PHAR.445 | June 1, 2025 |
| Burn Surgery (PDF) | CP.MP.186 | February 1, 2025 |
| C1 Esterase Inhibitors (Berinert Cinryze Haegarda Ruconest) (PDF) | CP.PHAR.202 | October 1, 2025 |
| Cabotegravir, Cabotegravir-Rilpivirine (Apretude Cabenuva) (PDF) | CP.PHAR.573 | April 1, 2025 |
| Cabazitaxel (Jevtana®) (PDF) | CP.PHAR.316 | July 1, 2025 |
| Canakinumab (Ilaris) (PDF) | CP.PHAR.246 | October 1, 2025 |
| Caplacizumab-yhdp (Cablivi) | CP.PHAR.416 | July 1, 2025 |
| Carbetocin (PDF) - coming soon | CP.PHAR.546 | Pending FDA Approval |
| Carfilzomib (Kyprolis) (PDF) | CP.PHAR.309 | March 1, 2025 |
| Casimersen (Amondys 45) (PDF) | CP.PHAR.470 | April 1, 2025 |
| Casirivimab and Imdevimab (REGEN-COV) (PDF) | CP.PHAR.520 | July 1, 2023 |
| Caudal or Interlaminar Epidural Steroid Injections (PDF) | CP.MP.164 | July 1, 2025 |
| Cemiplimab-rwlc (Libtayo) (PDF) | CP.PHAR.397 | January 1, 2025 |
| Cerliponase alfa (Brineura) (PDF) | CP.PHAR.338 | October 1, 2025 |
| Certolizumab (Cimzia) (PDF) | CP.PHAR.247 | July 1, 2024 |
| Cetuximab (Erbitux) (PDF) | CP.PHAR.317 | March 1, 2025 |
| Chloramphenicol Sodium Succinate (PDF) | CP.PHAR.388 | October 1, 2025 |
| Ciltacabtagene Autoleucel (Carvykti) (PDF) | CP.PHAR.533 | July 1, 2025 |
| Cipaglucosidase alfa-atga--miglustat (Pombiliti-Opfolda) (PDF) | CP.PHAR.567 | April 1, 2025 |
| Clinical Trials (PDF) | CP.MP.94 | August 1, 2025 |
| Cochlear Implanted Replacements (PDF) | AR.CP.MP.14 | September 1, 2024 |
| Collagenase Clostridium Histolyticum (Xiaflex) (PDF) | CP.PHAR.82 | October 1, 2025 |
| Compounded Medications (PDF) | CP.PMN.280 | April 1, 2025 |
| Concert Genetic Testing: Aortopathies and Connective Tissue Disorders (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Cardiac Disorders (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Dermatologic Conditions (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Epilepsy, Neurodegenerative, and Neuromuscular Conditions (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Exome and Genome Sequencing for the Diagnosis of Genetic Disorders (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Eye Disorders (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Gastroenterologic Disorders (non-cancerous) (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: General Approach to Genetic and Molecular Testing (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Hearing Loss (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Hematologic Conditions (non-cancerous) (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Hereditary Cancer Susceptibility (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Immune, Autoimmune, and Rheumatoid Disorders (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Kidney Disorders (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Lung Disorders (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Metabolic, Endocrine, and Mitochondrial Disorders (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Multisystem Inherited Disorders, Intellectual Disability, and Developmental Delay (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Pharmacogenetics (Version B) (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Preimplantation Genetic Testing (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Prenatal and Preconception Carrier Screening (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Prenatal Cell-Free DNA Testing (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetic Testing: Prenatal Diagnosis (via Amniocentesis, CVS, or PUBS) and Pregnancy Loss (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetic Testing: Skeletal Dysplasia and Rare Bone Disorders (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetics Oncology: Algorithmic Testing (PDF) | V1.2025 | March 1, 2025 |
| Concert Genetics Oncology: Cancer Screening (PDF) | AR.V1.2025 | March 1, 2025 |
| Concert Genetics Oncology: Circulating Tumor DNA and Circulating Tumor Cells (Liquid Biopsy) (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetics Oncology: Cytogenetic Testing (PDF) | V1.2025
| March 1, 2025 |
| Concert Genetics Oncology: Molecular Analysis of Solid Tumors and Hematologic Malignancies (PDF) | V1.2025
| March 1, 2025 |
| Concizumab (Alhemo) (PDF) | CP.PHAR.625 | April 1, 2025 |
| Copanlisib (Aliqopa) (PDF) | CP.PHAR.357 | March 1, 2025 |
| Corticosteroids for ophthalmic inj (Dextenza, Iluvien, Ozurdex, Retisert, Xipere, Yutiq) (PDF) | CP.PHAR.385 | October 1, 2025 |
| Corticotropin (H.P. Acthar, Purified Cortrophin Gel) (PDF) | CP.PHAR.168 | May 1, 2023 |
| Cosibelimab-Ipdl (Unloxcyt) (PDF) | CP.PHAR.711 | August 1, 2025 |
| Cosmetic and Reconstructive Procedures (PDF) | CP.MP.31 | October 1, 2024 |
| Cosyntropin (Cortrosyn) (PDF) | CP.PHAR.203 | June 1, 2025 |
Crizanlizumab-tmca (Adakveo) (PDF)
| CP.PHAR.449 | December 1, 2025 |
| Crizanlizumab-tmca (Adakveo) (PDF) | CP.PHAR.449 | Version effective until December 1, 2025 |
| Cytomegalovirus Immune Globulin (Cytogam) (PDF) | CP.PHAR.277 | October 1, 2025 |
| Dalteparin (Fragmin) (PDF) | CP.PHAR.225 | March 1, 2022 |
| Daprodustat (Jesduvroq) (PDF) | CP.PHAR.628 | July 1, 2025 |
| Daptomycin (Cubicin RF) (PDF) | CP.PHAR.351 | October 1, 2025 |
| Daratumumab (Darzalex), Daratumumab/Hyaluronidase-fihj (Darzalex Faspro) (PDF) | CP.PHAR.310 | October 1, 2025 |
| Darbepoetin Alfa (Aranesp) (PDF) | CP.PHAR.236 | September 1, 2025 |
| Datopotamab Deruxtecan-dlnk (Datroway) (PDF) | CP.PHAR.715 | November 1, 2025 |
| Daunorubicin and Cytarabine (Vyxeos) (PDF) | CP.PHAR.352 | January 1, 2025 |
| DaxibotulinumtoxinA-lanm (Daxxify) (PDF) | CP.PHAR.651 | January 1, 2025 |
| Deep Transcranial Magnetic Stimulation for the Treatment of Obsessive Compulsive Disorder (PDF) | CP.BH.201 | July 1, 2025 |
| Deferoxamine (Desferal) (PDF) | CP.PHAR.146 | December 1, 2025 |
| Deferoxamine (Desferal) (PDF) | CP.PHAR.146 | Version effective until December 1, 2025 |
| Degarelix (Firmagon) (PDF) | CP.PHAR.170 | December 1, 2023 |
| Delafloxacin (Baxdela) (PDF) | CP.PMN.115 | October 1, 2025 |
| Delandistrogene Moxeparvovec-rokl (Elevidys) (PDF) | CP.PHAR.593 | October 1, 2025 |
| Denileukin Diftitox-cxdl (Lymphir) (PDF) | CP.PHAR.693 | May 1, 2025 |
| Denosumab (Prolia, Xgeva) (PDF) | CP.PHAR.58 | July 1, 2025 |
| Desmopressin Acetate (DDAVP, Stimate, Nocdurna, Noctiva) (PDF) | CP.PHAR.214 | June 1, 2025 |
| Dexrazoxane (Zinecard, Totect) (PDF) | CP.PHAR.418 | September 1, 2025 |
| Diaphragmatic/Phrenic Nerve Stimulation (PDF) | CP.MP.203 | September 1, 2025 |
| Disc Decompression Procedures (PDF) | CP.MP.114 | June 1, 2025 |
| Discography (PDF) | CP.MP.115 | June 1, 2025 |
| Donanemab-azbt (Kisunla) (PDF) | CP.PHAR.594 | March 1, 2025 |
| Dostarlimab-gxly (Jemperli) (PDF) | CP.PHAR.540 | December 1, 2025 |
| Dostarlimab-gxly (Jemperli) (PDF) | CP.PHAR.540 | Version effective until December 1, 2025 |
| Durable Medical Equipment and Orthotics and Prosthetics Guidelines (PDF) | CP.MP.107 | May 1, 2025 |
| Durvalumab (Imfinzi) (PDF) | CP.PHAR.339 | September 1, 2025 |
| Ecallantide (Kalbitor) (PDF) | CP.PHAR.177 | October 1, 2025 |
| Eculizumab (Soliris) (PDF) | CP.PHAR.97 | May 1, 2025 |
| Edaravone (Radicava) (PDF) | CP.PHAR.343 | September 1, 2025 |
| Efgartigimod alfa-fcab (Vyvgart) (PDF) | CP.PHAR.555
| July 1, 2025 |
| Eladocagene Exuparvovec-tneq (Kebilidi) (PDF) | CP.PHAR.595 | May 1, 2025 |
| Elapegademase-lvlr (Revcovi) (PDF) | CP.PHAR.419 | July 1, 2025 |
| Electric Tumor Treating Fields (Optune) (PDF) | CP.MP.145 | March 1, 2025 |
| Elivaldogene autotemcel (Skysona) (PDF) | CP.PHAR.556 | January 1, 2025 |
| Elosulfase Alfa (Vimizim) (PDF) | CP.PHAR.162 | July 1, 2025 |
| Elosulfase Alfa (Vimizim) (PDF) | CP.PHAR.162 | July 1, 2025 |
| Elotuzumab (Empliciti) (PDF) | CP.PHAR.308 | March 1, 2025 |
| Elranatamab-bcmm (Elrexfio) (PDF) | CP.PHAR.652 | January 1, 2025 |
| Emapalumab-lzsg (Gamifant) (PDF) | CP.PHAR.402 | October 1, 2025 |
| Enfortumab Vedotin-ejfv (Padcev) (PDF) | CP.PHAR.455 | April 1, 2025 |
| Enfuvirtide (Fuzeon) (PDF) | CP.PHAR.41 | October 1, 2025 |
| Enoxaparin (Lovenox) (PDF) | CP.PHAR.224 | April 1, 2025 |
| Epcoritamab-bysp (Epkinly) (PDF) | CP.PHAR.634 | October 1, 2025 |
| Epoetin Alfa (Epogen® and Procrit) (PDF) | CP.PHAR.237 | August 1, 2025 |
| Epoprostenol (Flolan, Veletri) (PDF) | CP.PHAR.192 | April 1, 2025 |
| EPSDT Benefit for Pediatric Members (PDF) | CP.PMN.234 | July 1, 2025 |
| Eptinezumab-jjmr (Vyepti) (PDF) | CP.PHAR.489 | March 1, 2025 |
| Eribulin Mesylate (Halaven) (PDF) | CP.PHAR.318 | January 1, 2025 |
| Erwinia Asparaginase (Erwinaze) (PDF) | CP.PHAR.301 | April 1, 2025 |
| Etelcalcetide (Parsabiv) (PDF) | CP.PHAR.379 | October 1, 2025 |
| Eteplirsen (Exondys 51) (PDF) | CP.PHAR.288 | April 1, 2025 |
| Etranacogene Dezaparvovec (Hemgenix) (PDF) | CP.PHAR.580 | April 1, 2025 |
| Evinacumab-dgnb (Evkeeza) (PDF) | CP.PHAR.511 | April 1, 2025 |
| Exagamglogene Autotemcel (Exa-Cel) (PDF) | CP.PHAR.603 | June 1, 2025 |
| Experimental Technologies (PDF) | CP.MP.36 | March 1, 2025 |
| Facet Joint Interventions (PDF) | CP.MP.171 | July 1, 2025 |
| Facility-based Sleep Studies for Obstructive Sleep Apnea (PDF) | CP.MP.248 | March 1, 2025 |
| Factor VIIa, Recombinant (NovoSeven RT, SevenFact) (PDF) | CP.PHAR.220 | June 1, 2025 |
| Factor VIII (Human Recombinant) (PDF) | CP.PHAR.215 | May 1, 2025 |
| Factor VIII/von Willebrand Factor Complex (Human - Alphanate®, Humate-P®, Wilate®) (PDF) | CP.PHAR.216 | June 1, 2025 |
| Factor IX (Human, Recombinant) (PDF) | CP.PHAR.218 | April 1, 2025 |
| Factor IX Complex, Human (Profilnine) (PDF) | CP.PHAR.219 | April 1, 2025 |
| Factor XIII, Human (Corifact®) (PDF) | CP.PHAR.221 | April 1, 2025 |
| Factor XIII A-Subunit, Recombinant (Tretten®) (PDF) | CP.PHAR.222 | April 1, 2025 |
| Family Centered Treatment In Lieu of Services (PDF) | ARTC.UM.21 | Janurary 1, 2026 |
| Fam-Trastuzumab Deruxtecan-nxki (Enhertu) (PDF) | CP.PHAR.456 | April 1, 2025 |
| Faricimab (Vabysmo) (PDF) | CP.PHAR.581 | April 1, 2025 |
| Fecal Incontinence Treatments (PDF) | CP.MP.137 | October 1, 2025 |
| Ferric Carboxymaltose (Injectafer) (PDF) | CP.PHAR.234 | April 1, 2025 |
| Ferric Derisomaltose (Monoferric) (PDF) | CP.PHAR.480 | July 1, 2025 |
| Ferric Pyrophosphate Citrate (Triferic) (PDF) | CP.PHAR.624 | July 1, 2025 |
| Ferumoxytol (Feraheme) (PDF) | CP.PHAR.165 | April 1, 2025 |
| Fertility Preservation (PDF) | CP.MP.130 | March 1, 2025 |
| Fetal Surgery in Utero for Prenatally Diagnosed Malformations (PDF) | CP.MP.129 | July 1, 2025 |
| Fibrinogen concentrate (human) (Fibryga, RiaSTAP) (PDF) | CP.PHAR.526 | July 1, 2025 |
| Fidanacogene Elaparvovec-dzkt (Beqvez) (PDF) | CP.PHAR.643 | January 1, 2025 |
| Filgrastim (Neupogen), Filgrastim-sndz (Zarxio), Tbo-filgrastim (Granix), Filgrastim-aafi (Nivestym), Filgrastim-ayow (Releuko), Filgrastim-txid (Nypozi) (PDF) | CP.PHAR.297 | October 1, 2025 |
| Fitusiran (Qfitlia) (PDF) | CP.PHAR.706 | November 1, 2025 |
| Fondaparinux (Arixtra) (PDF) | CP.PHAR.226 | March 1, 2022 |
| Fosdenopterin (Nulibry) (PDF) | CP.PHAR.471 | November 1, 2025 |
| Fulvestrant (Faslodex Injection) (PDF) | CP.PHAR.424 | December 1, 2025 |
| Fulvestrant (Faslodex Injection) (PDF) | CP.PHAR.424 | Version effective until December 1, 2025 |
| Galsulfase (Naglazyme) (PDF) | CP.PHAR.161 | July 1, 2025 |
| Galsulfase (Naglazyme) (PDF) | CP.PHAR.161 | July 1, 2025 |
| Gastric Electrical Stimulation (PDF) | CP.MP.40 | June 1, 2025 |
| Gemtuzumab (Mylotarg) (PDF) | CP.PHAR.358 | January 1, 2025 |
| Gender-Affirming Procedures (PDF) | CP.MP.95 | September 1, 2025 |
| Givosiran (Givlaari) (PDF) | CP.PHAR.457 | April 1, 2025 |
| Glofitamab-gxbm (Columvi) (PDF) | CP.PHAR.636 | October 1, 2025 |
| Golodirsen (Vyondys 53) (PDF) | CP.PHAR.453 | April 1, 2025 |
| Golimumab (Simponi, Simponi Aria) (PDF) | CP.PHAR.253 | September 1, 2025 |
| Goserelin Acetate (Zoladex) (PDF) | CP.PHAR.171 | June 1, 2025 |
| Granisetron (Sancuso, Sustol) (PDF) | CP.PMN.74 | October 1, 2025 |
| Hemin (Panhematin) (PDF) | CP.PHAR.181 | April 1, 2025 |
| Histrelin (Vantas, Supprelin LA) (PDF) | CP.PHAR.172 | July 1, 2025 |
| Home and Community Based Services (HCBS) (PDF) | AR.CP.BH.503 | November 1, 2025 |
| Home Births (PDF) | CP.MP.136 | June 1, 2025 |
| Home Ventilators (PDF) | AR.CP.MP.184 | August 1, 2025 |
| Hospice Services (PDF) | CP.MP.54 | August 1, 2025 |
| Hyaluronate Derivatives (PDF) | CP.PHAR.05 | January 1, 2025 |
| Hydroxyprogesterone caproate (Makena) (PDF) | CP.PHAR.14 | July 1, 2025 |
| Hyperhidrosis Treatments (PDF) | CP.MP.62 | May 1, 2025 |
| ibalizumab-uiyk (Trogarzo) (PDF) | CP.PHAR.378 | October 1, 2025 |
| Ibandronate Injection (Boniva) (PDF) | CP.PHAR.189 | October 1, 2025 |
| Idecabtagene vicleucel (Abecma) (PDF) | CP.PHAR.481 | July 1, 2025 |
| Idursulfase (Elaprase) (PDF) | CP.PHAR.156 | July 1, 2025 |
| Iloprost (Ventavis) (PDF) | CP.PHAR.193 | April 1, 2025 |
| Imetelstat (Rytelo) (PDF) | CP.PHAR.690 | October 1, 2025 |
| Imiglucerase (Cerezyme) (PDF) | CP.PHAR.154 | July 1, 2025 |
| Immune Globulins (PDF) | CP.PHAR.103 | October 1, 2025 |
| Immune Globulins for PANS/PANDAS (PDF) | AR.CP.PHAR.103 | September 1, 2025 |
| Implantable Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea (PDF) | CP.MP.180 | August 1, 2025 |
| Implantable Intrathecal or Epidural Pain Pump (PDF) | CP.MP.173 | February 1, 2025 |
| Implantable Loop Recorder (PDF) | CP.MP.243 | February 1, 2025 |
| Implantable Wireless Pulmonary Artery Pressure Monitoring (PDF) | CP.MP.160 | April 1, 2025 |
| Inclisiran (Leqvio) (PDF) | CP.PHAR.568 | October 1, 2025 |
| IncobotulinumtoxinA (Xeomin) (PDF) | CP.PHAR.231 | October 1, 2025 |
| Inotersen (Tegsedi) (PDF) | CP.PHAR.405 | February 1, 2023 |
| Inebilizumab-cdon (Uplizna) (PDF) | CP.PHAR.458 | December 1, 2025 |
| Inebilizumab-cdon (Uplizna) (PDF) | CP.PHAR.458 | Version effective until December 1, 2025 |
| Infertility and Fertility Preservation (PDF) | CP.PHAR.131 | March 1, 2025 |
| Infliximab (Remicade, Inflectra, Renflexis) (PDF) | CP.PHAR.254 | September 1, 2025 |
| Inotuzumab Ozogamicin (Besponsa) (PDF) | CP.PHAR.359 | January 1, 2025 |
| Insulin Delivery Systems (V-Go, Omnipod, InPen) (PDF) | CP.PHAR.534 | November 1, 2025 |
| Insulin detemir (Levemir) (PDF) | HIM.PA.171 | June 1, 2025 |
| Intensity-Modulated Radiotherapy (PDF) | CP.MP.69 | July 1, 2025 |
| Interferon Gamma- 1b (Actimmune) (PDF) | CP.PHAR.52 | April 1, 2025 |
| Intradiscal Steroid Injections for Pain Management (PDF) | CP.MP.167 | September 1, 2025 |
| Iobenguane I-131 (Azedra) (PDF) | CP.PHAR.459 | April 1, 2025 |
| Ipilimumab (Yervoy) (PDF) | CP.PHAR.319 | October 1, 2025 |
| Ipilimumab (Yervoy) (PDF) | CP.PHAR.319 | Version effective until October 1, 2025 |
| Irinotecan Liposome (Onivyde) (PDF) | CP.PHAR.304 | January 1, 2025 |
| Isatuximab-irfc (Sarclisa)(PDF) | CP.PHAR.482 | July 1, 2025 |
| Isavuconazonium (Cresemba) (PDF) | CP.PMN.154
| July 1, 2025 |
| IV Moderate Sedation, IV Deep Sedation, and General Anesthesia for Dental Procedures (PDF) | AR.CP.MP.61 | August 1, 2025 |
| Ixekizumab (Taltz) (PDF) | CP.PHAR.257 | June 1, 2023 |
| Ketamine (Ketalar) (PDF) | CP.PMN.296 | October 1, 2025 |
| Lanadelumab-fylo (Takhzyro) (PDF) | CP.PHAR.396 | October 1, 2025 |
| Lanreotide (Somatuline Depot) (PDF) | CP.PHAR.391 | January 1, 2025 |
| Lantidra (donislecel): Allogenic Pancreatic Islet Cellular Therapy (PDF) | CP.MP.250 | September 1, 2025 |
| Laronidase (Aldurazyme) (PDF) | CP.PHAR.152 | July 1, 2025 |
| Lecanemab-irmb (Leqembi) (PDF) | CP.PHAR.596 | September 1, 2025 |
| Lefamulin (Xenleta) (PDF) | CP.PMN.219 | October 1, 2025 |
| Letermovir (Prevymis) (PDF) | CP.PHAR.367 | October 1, 2025 |
| Letermovir (Prevymis) (PDF) | CP.PHAR.367 | Version effective until October 1, 2025 |
| Leucovorin Injection (PDF) | CP.PHAR.393 | January 1, 2025 |
| Leuprolide Acetate (Eligard, Fensolvi, Lupron Depot, Lupron Depot-Ped), Leuprolide mesylate (Camcevi) (PDF) | CP.PCH.53 | June 1, 2025 |
| Leuprolide Acetate (Lupron, Lupron Depot, Eligard, Lupaneta Pack, Fensolvi) (PDF) | CP.PHAR.173 | May 1, 2025 |
| Levoleucovorin (Fusilev, Khapzory) (PDF) | CP.PHAR.151 | January 1, 2025 |
| Lifileucel (Amtagvi) (PDF) | CP.PHAR.598 | January 1, 2025 |
| Linezolid (Zyvox) (PDF) | CP.PMN.27 | October 1, 2025 |
| Linvoseltamab-gcpt (Lynozyfic) (PDF) | CP.PHAR.743 | November 1, 2025 |
| Liposuction for Lipedema (PDF) | CP.MP.244 | June 1, 2025 |
| Lisocabtagene maraleucel (Breyanzi) (PDF) | CP.PHAR.483 | July 1, 2025 |
| Lofexidine(Lucemyra) (PDF) | CP.PMN.152 | June 1. 2025 |
| Loncastuximab tesirine-lpyl (Zynlonta) (PDF) | CP.PHAR.539 | October 1, 2025 |
| Lovotibeglogene Autotemcel (Lovo-Cel) (PDF) | CP.PHAR.627 | June 1, 2025 |
| Lumasiran (Oxlumo) (PDF) | CP.PHAR.473 | April 1, 2025 |
| Lurbinectedin (Zepzelca) (PDF) | CP.PHAR.500 | October 1, 2025 |
| Luspatercept-aamt (Reblozyl) (PDF) | CP.PHAR.450 | April 1, 2025 |
| Lutetium Lu 177 Dotatate (Lutathera) (PDF) | CP.PHAR.384 | October 1, 2025 |
| Lutetium Lu 177 vipivotide tetraxetan (Pluvicto) (PDF) | CP.PHAR.582 | July 1, 2025 |
| Lysis of Epidural Lesions (PDF) | CP.MP.116 | June 1, 2025 |
| Margetuximab-cmkb (Margenza) (PDF) | CP.PHAR.522 | April 1, 2025 |
| Marstacimab-hncq (Hympavzi) (PDF) | CP.PHAR.674 | August 1, 2025 |
| Mecasermin (Increlex) (PDF) | CP.PHAR.150 | October 1, 2025 |
| Mechanical Stretching Devices for Joint Stiffness and Contracture (PDF) | CP.MP.144 | May 1, 2025 |
| Melphalan (Hepzato) (PDF) | CP.PHAR.653 | January 1, 2025 |
| Melphalan flufenamide (Pepaxto) (PDF) | CP.PHAR.535 | July 1, 2025 |
| Mepolizumab (Nucala) (PDF) | CP.PHAR.200 | April 1, 2022 |
| Methoxy polyethylene glycol-epoetin beta (Mircera) (PDF) | CP.PHAR.238 | September 1, 2025 |
| Metreleptin (Myalept) (PDF) | CP.PHAR.425 | October 1, 2025 |
| Mirikizumab-mrkz (Omvoh) (PDF) | CP.PHAR.662 | September 1, 2025 |
| Mirvetuximab soravtansine-gynx (Elahere) (PDF) | CP.PHAR.617 | April 1, 2025 |
| Mitomycin Instillation Solution (Jelmyto, Zusduri) (PDF) | CP.PHAR.495 | December 1, 2025 |
| Mitomycin Instillation Solution (Jelmyto, Zusduri) (PDF) | CP.PHAR.495 | Version effective until December 1, 2025 |
| Mitoxantrone (Novantrone) (PDF) | CP.PHAR.258 | July 1, 2025 |
| Mogamulizumab-kpkc (Poteligeo) (PDF) | CP.PHAR.139 | March 1, 2025 |
| Mometasone Furoate (Sinuva) (PDF) | CP.PHAR.448 | October 1, 2025 |
| Mosunetuzumab-axgb (Lunsumio) (PDF) | CP.PHAR.618 | April 1, 2025 |
| Motixafortide (Aphexda) (PDF) | CP.PHAR.655 | January 1, 2025 |
| Moxetumomab Pasudotox-tdfk (Lumoxiti) (PDF) | CP.PHAR.398 | January 1, 2025 |
| Multiple Sleep Latency Testing (PDF) | CP.MP.24 | September 1, 2025 |
| Nadofaragene Firadenovec (Instiladrin)(PDF) | CP.PHAR.461 | March 1, 2025 |
| Nafarelin Acetate (Synarel) (PDF) | CP.PHAR.174 | June 1. 2025 |
| Natalizumab (Tysabri, Tyruko) (PDF) | CP.PHAR.259 | October 1, 2025 |
| Naxitamab-gqgk (Danyelza) (PDF) | CP.PHAR.523 | April 1, 2025 |
| Necitumumab (Portrazza) (PDF) | CP.PHAR.320 | January 1, 2025 |
| Nedosiran (Rivfloza) (PDF) | CP.PHAR.619 | September 1, 2025 |
| Nemolizumab-ito (Nemluvio) (PDF) | CP.PHAR.703 | January 1, 2025 |
| Neuromuscular and Peroneal Nerve Electrical Stimulation (NMES) (PDF) | CP.MP.48 | July 1, 2025 |
| Netupitant and Palonosetron (Akynzeo), Fosnetupitant and Palonosetron (Akynzeo IV) (PDF) | CP.PMN.158 | October 1, 2025 |
| Nerve Blocks and Neurolysis for Pain Management (PDF) | CP.MP.170 | April 1, 2025 |
| Nipocalimab-aahu (Imaavy) (PDF) | CP.PHAR.720 | Novmeber 1, 2025 |
| Nirsevimab (Beyfortus) 08.07.23 (PDF) | CP.PHAR.614 | October 1, 2025 |
| Nivolumab, Nivolumab Hyaluronidase-nvhy (PDF) | CP.PHAR.121 | December 1, 2025 |
| Nivolumab, Nivolumab Hyaluronidase-nvhy (PDF) | CP.PHAR.121 | Version effective until December 1, 2025 |
| Nivolumab and Relatlimab (Opdualag) (PDF) | CP.PHAR.588 | October 1, 2025 |
| No Coverage Criteria (PDF) | CP.PMN.255 | May 1, 2025 |
| Nogapendekin alfa inbakicept-pmln (Anktiva) (PDF) | CP.PHAR.684 | October 1, 2025 |
| Nonmyeloablative Allogeneic Stem Cell Transplants (PDF) | CP.MP.141 | July 1, 2024 |
| Nusinersen (Spinraza®) (PDF) | CP.PHAR.327 | October 1, 2025 |
Obecabtagene autoleucel (Aucatzyl) (PDF)
| CP.PHAR.675 | August 1, 2025 |
| Obinutuzumab (Gazyva) (PDF) | CP.PHAR.305 | January 1, 2025 |
| Obstetrical Home Care Programs (PDF) | CP.MP.91 | February 1, 2025 |
| Ocrelizumab (Ocrevus), Ocrelizumab-hyaluronidase-ocsq (Ocrevus Zunovo) (PDF) | CP.PHAR.335 | October 1, 2025 |
| Octreotide Acetate (Sandostatin, Sandostatin LAR Depot, Bynfezia, Mycapssa) (PDF) | CP.PHAR.40 | June 1, 2025 |
| Ofatumumab (Arzerra, Kesimpta) (PDF) | CP.PHAR.306 | October 1, 2025 |
| Off-Label Use (PDF) | CP.PMN.53 | March 1, 2025 |
| Olaparib (Lynparza) (PDF) | CP.PHAR.360 | May 1, 2023 |
| Olezarsen (Tryngolza) (PDF) | CP.PHAR.689 | Aril 1, 2025 |
| Olipudase alfa-rpcp (Xenpozyme) (PDF) | CP.PHAR.586 | October 1, 2025 |
| Omadacycline (Nuzyra) (PDF) | CP.PMN.188 | October 1, 2025 |
| Omalizumab (Xolair) (PDF) | CP.PHAR.01 | November 1, 2025 |
| Omecetaxine (Synribo) (PDF) | CP.PHAR.108 | Septrember 1, 2025 |
| Allogeneic Hematopoietic Progenitor Cell Therapy (PDF) | CP.MP.249 | October 1, 2025 |
| OnabotulinumtoxinA (Botox) (PDF) | CP.PHAR.232 | October 1, 2025 |
| Onasemnogene Abeparvovec (Zolgensma) (PDF) | CP.PHAR.421 | July 1, 2025 |
| Ophthalmic Riboflavin (Photrexa, Photrexa Viscous) | CP.PHAR.536 | July 1, 2025 |
| Orthognathic Surgery (PDF) | CP.MP.202 | October 1, 2024 |
| Osteogenic Stimulation (PDF) | CP.MP.194 | August 1, 2025 |
| Outpatient Cardiac Rehabilitation (PDF) | CP.MP.176 | July 1, 2025 |
| Outpatient Oxygen Use (PDF) | CP.MP.190 | February 1, 2025 |
| Paclitaxel protein-bound (Abraxane) (PDF) | CP.PHAR.176 | October 1, 2025 |
| Panitumumab (Vectibix) (PDF) | CP.PHAR.321 | May 1, 2025 |
| Panniculectomy (PDF) | CP.MP.109 | October 1, 2024 |
| Paricalcitol Injection (Zemplar) (PDF) | CP.PHAR.270 | October 1, 2025 |
| Pasireotide (Signifor, Signifor LAR) (PDF) | CP.PHAR.332 | January 1, 2025 |
| Patisiran (Onpattro) (PDF) | CP.PHAR.395 | July 1, 2025 |
| Peanut Allergen Powder-dnfp (Palforzia)(PDF) | CP.PMN.220 | March 1, 2021 |
| Pediatric Oral Function Therapy (PDF) | CP.MP.188 | June 1, 2025 |
| Pegaspargase (Oncaspar), Calaspargase Pegol-mknl (Asparlas) (PDF) | CP.PHAR.353 | March 1, 2025 |
| Pegcetacoplan (Empaveli, Syfovre) (PDF) | CP.PHAR.524 | December 1, 2025 |
| Pegcetacoplan (Empaveli, Syfovre) (PDF) | CP.PHAR.524 | Version effective until December 1, 2025 |
| Pegfilgrastim/Biosimilars, Eflapegrastim, Efbemalenograstim (PDF) | CP.PHAR.296 | October 1, 2025 |
| Pegloticase (Krystexxa) (PDF) | CP.PHAR.115 | April 1, 2025 |
| Pegunigalsidase alfa-iwxj (Elfabrio) (PDF) | CP.PHAR.512 | September 1, 2025 |
| Pegvaliase-pqpz (Palynziq) (PDF) | CP.PHAR.140 | January 1, 2025 |
| Pegvisomant (Somavert) (PDF) | CP.PHAR.389 | January 1, 2025 |
| Pembrolizumab (Keytruda®) (PDF) | CP.PHAR.322 | October 1, 2025 |
| Pemetrexed (Alimta, Pemfexy) (PDF) | CP.PHAR.368 | June 1, 2025 |
| Penpulimab-kcqx (PDF) | CP.PHAR.732 | October 1, 2025 |
| Percutaneous Left Atrial Appendage Closure for Stroke Prevention (PDF) | CP.MP.147 | August 1, 2025 |
| Personal Care Services Authorization (PDF) | ARTC.UM.19 | August 1, 2025 |
| Pertuzumab (Perjeta) (PDF) | CP.PHAR.227 | September 1, 2025 |
| Pertuzumab-trastuzumab-hyaluronidase-zzxf (Phesgo) (PDF) | CP.PHAR.501 | October 1, 2025 |
| Physical, Occupational, and Speech Therapy Services (PDF) | CP.MP.49 | August 1, 2024 |
| Plasminogen (Ryplazim) (PDF) | CP.PHAR.513 | January 1, 2025 |
| Plerixafor (Mozobil) (PDF) | CP.PHAR.323 | October 1, 2025 |
| Polatuzumab Vedotin-piiq (Polivy) (PDF) | CP.PHAR.433 | December 1, 2025 |
| Polatuzumab Vedotin-piiq (Polivy) (PDF) | CP.PHAR.433 | Version effective until December 1, 2025 |
| Posterior Tibial Nerve Stimulation for Voiding Dysfunction (PDF) | CP.MP.133 | September 1, 2025 |
| Pozelimab (REGN3918) (PDF) | CP.PHAR.626 | September 1, 2025 |
| Prademagene Zamikeracel (Zevaskyn) (PDF) | CP.PHAR.609 | October 1, 2025 |
| Pralatrexate (Folotyn) (PDF) | CP.PHAR.313 | March 1, 2025 |
| Protein C Concentrate, Human (Ceprotin) PDF) | CP.PHAR.330 | April 1, 2025 |
| Proton and Neutron Beam Therapies (PDF) | CP.MP.70 | May 1, 2025 |
| Radiation Therapy for Skin Cancer | CP.MP.251 | October 1, 2025 |
| Ramucirumab (Cyramza) (PDF) | CP.PHAR.119 | July 1, 2025 |
| Ranibizumab (Byooviz, Lucentis, Susvimo) (PDF) | CP.PHAR.186 | May 1, 2025 |
| Ravulizumab-cwvz (Ultomiris) (PDF) | CP.PHAR.415 | December 1, 2025 |
| Ravulizumab-cwvz (Ultomiris) (PDF) | CP.PHAR.415 | Version effective until December 1, 2025 |
| Reduction Mammoplasty and Gynecomastia Surgery (PDF) | CP.MP.51 | October 1, 2025 |
| Remestemcel-L (Ryoncil) (PDF) | CP.PHAR.474 | November 1, 2025 |
| Repair of Nasal Valve Compromise (PDF) | CP.MP.210 | June 1, 2025 |
| Reslizumab (Cinqair) (PDF) | CP.PHAR.223 | April 1, 2025 |
| Respiratory Syncytial Virus Vaccine (Abrysvo) C (PDF) | CP.PHAR.658 | January 1, 2025 |
| Retifanlimab-dlwr (Zynyz) (PDF) | CP.PHAR.629 | August 1, 2025 |
| Revakinagene Taroretcel-lwey (Encelto) (PDF) | CP.PHAR.697 | July 1, 2025 |
| Rilonacept (Arcalyst) (PDF) | CP.PHAR.266 | September 1, 2025 |
| RimabotulinumtoxinB (Myobloc) (PDF) | CP.PHAR.233 | October 1, 2025 |
| Risankizumab-rzaa (Skyrizi) (PDF) | CP.PHAR.426 | September 1, 2025 |
| Risdiplam (Evrysdi) (PDF) | CP.PHAR.477 | July 1, 2025 |
| Rituximab (Rituxan), Rituxan/Hyaluronidase (Rituxan Hycela) (PDF) | CP.PHAR.260 | October 1, 2025 |
| Rolapitant (Varubi) (PDF) | CP.PMN.102 | October 1, 2025 |
| Romidepsin (Istodax) (PDF) | CP.PHAR.314 | January 1, 2025 |
| Romiplostim (Nplate®) (PDF) | CP.PHAR.179 | April 1, 2025 |
| Ropeginterferon alfa-2b-njft (Besremi) (PDF) | CP.PHAR.570 | April 1, 2025 |
| Rozanolixizumab-noli (Rystiggo) (PDF) | CP.PHAR.648 | March 1, 2025 |
| Sacituzumab Govitecan-hziy (Trodelvy) (PDF) | CP.PHAR.475 | June 1, 2025 |
| Sacroiliac Joint Fusion (PDF) | CP.MP.126 | June 1, 2025 |
| Sacroiliac Joint Interventions for Pain Management (PDF) | CP.MP.166 | September 1, 2024 |
| Sargramostim (Leukine) (PDF) | CP.PHAR.295 | December 1, 2025 |
| Sargramostim (Leukine) (PDF) | CP.PHAR.295 | Version effective until December 1, 2025 |
| Satralizumab-mwge (Enspryng) (PDF) | CP.PHAR.463 | December 1, 2025 |
| Satralizumab-mwge (Enspryng) (PDF) | CP.PHAR.463 | Version effective until December 1, 2025 |
| Sclerotherapy and Chemical Endovenous Ablation for Varicose Veins and Other Symptomatic Venous Disorders (PDF) | CP.MP.146 | May 1, 2025 |
| Sebelipase Alfa (Kanuma) (PDF) | CP.PHAR.159 | July 1, 2025 |
| Sebelipase Alfa (Kanuma) (PDF) | CP.PHAR.159 | July 1, 2025 |
| Secukinumab (Cosentyx) (PDF) | CP.PHAR.261 | July 1, 2024 |
| Selective Dorsal Rhizotomy for Spasticity in Cerebral Palsy (PDF) | CP.MP.174 | February 1, 2025 |
| Selective Nerve Root Blocks and Transforaminal Epidural Steroid Injections (PDF) | CP.MP.165 | September 1, 2024
|
| Setmelanotide (Imcivree) (PDF) | CP.PHAR.491 | December 1, 2022 |
| Sipuleucel-T (Provenge) (PDF) | CP.PHAR.120 | July 1, 2025 |
| Siltuximab (Sylvant) (PDF) | CP.PHAR.329 | April 1, 2025 |
| Sirolimus Protein-Bound Particles (Fyarro), topical gel (Hyftor) (PDF) | CP.PHAR.574 | April 1, 2025 |
| Skin and Soft Tissue Substitutes for Chronic Wounds (PDF) | CP.MP.185 | August 1, 2025 |
| Sodium thiosulfate (Pedmark) (PDF) | CP.PHAR.610 | April 1, 2025 |
| Sotatercept (ACE-011) (PDF) - coming soon | CP.PHAR.657 | Pending FDA Approval |
| Sotrovimab (VIR-7831) (PDF) | CP.PHAR.541 | July 1, 2023 |
| Spesolimab-sbzo (Spevigo) (PDF) | CP.PHAR.606 | October 1, 2025 |
| Spinal Cord, Peripheral Nerve, and Percutaneous Electrical Nerve Stimulation (PDF) | CP.MP.117 | February 1, 2025 |
| Stereotactic Body Radiation Therapy (PDF) | CP.MP.22 | December 1, 2024 |
| Sutimlimab-jome (Enjaymo) (PDF) | CP.PHAR.503 | July 1, 2025 |
| Tafasitamab-cxix (Monjuvi) (PDF) | CP.PHAR.508 | October 1, 2025 |
| Taletrectinib (Ibtrozi) (PDF) | CP.PHAR.740 | October 1, 2025 |
| Taliglucerase Alfa (Elelyso) (PDF) | CP.PHAR.157 | October 1, 2025 |
| Talimogene laherparepvec (Imlygic) (PDF) | CP.PHAR.542 | October 1, 2025 |
| Talquetamab-tgvs (Talvey) (PDF) | CP.PHAR.649 | March 1, 2025 |
| Tarlatamab-dlle (Imdelltra) (PDF) | CP.PHAR.685 | October 1, 2025 |
| Tebentafusp-(Kimmtrak) (PDF) | CP.PHAR.575 | July 1, 2025 |
| Teclistamab-cqyv (Tecvayli) (PDF) | CP.PHAR.611 | April 1, 2025 |
| Tedizolid (Sivextro) (PDF) | CP.PMN.62 | October 1, 2025 |
| Teduglutide (Gattex) (PDF) | CP.PHAR.114 | April 1, 2025 |
| Telisotuzumab Vedotin-tllv (Emrelis) (PDF) | CP.PHAR.733 | November 1, 2025 |
| Temozolomide (Temodar) (PDF) | CP.PHAR.77 | September 1, 2025 |
| Temsirolimus (Torisel) (PDF) | CP.PHAR.324 | January 1, 2025 |
| Teplizumab-mzwv (Tzield) (PDF) | CP.PHAR.492 | April 1, 2025 |
| Teprotumumab (Tepezza) (PDF) | CP.PHAR.465 | April 1, 2025 |
| Testosterone (Androderm) (PDF) | HIM.PA.87 | June 1, 2025 |
| Testosterone (Testopel, Jatenzo) (PDF) | CP.PHAR.354 | June 1, 2025 |
| Tezepelumab (Tezspire) (PDF) | CP.PHAR.576 | April 1, 2025 |
| Thyrotropin alfa (Thyrogen) (PDF) | CP.PHAR.95 | October 1, 2025 |
| Tildrakizumab-asmn (Ilumya) (PDF) | CP.PHAR.386 | July 1, 2024 |
| Tisagenlecleucel (Kymriah) (PDF) | CP.PHAR.361 | June 1, 2025 |
| Tislelizumab-jsgr (Tevimbra) (PDF) | CP.PHAR.687 | October 1, 2025 |
| Tisotumab Vedotin-tftv (Tivdak) (PDF) | CP.PHAR.561 | March 1, 2025 |
| Tixagevimab-Cilgavimab (Evusheld) (PDF) | CP.PHAR.571 | July 1, 2023 |
| Tobramycin (Bethkis, Kitabis Pak, TOBI, TOBI Podhaler) (PDF) | CP.PHAR.211 | March 1, 2022 |
| Tocilizumab (Actemra) (PDF) | CP.PHAR.263 | September 1, 2025 |
| Tofersen (Qalsody) (PDF) | CP.PHAR.591 | January 1, 2025 |
| Topotecan (Hycamtin) (PDF) | CP.PHAR.64 | July 1, 2025 |
| Toripalimab (Loqtorzi) (PDF) | CP.PHAR.668 | April 1, 2025 |
| Total Parenteral Nutrition and Intradialytic Parenteral Nutrition (PDF) | CP.MP.163 | April 1, 2025 |
| Trabectedin (Yondelis) (PDF) | CP.PHAR.204 | April 1, 2025 |
| Tralokinumab-ldrm (Adbry) (PDF) | CP.PHAR.577 | June 1, 2022 |
| Transcranial Magnetic Stimulation for Treatment Resistant Major Depression (PDF) | CP.BH.200 | July 1, 2025 |
| Trastuzumab (Herceptin), Trastuzumab-dkst (Ogivri) (PDF) | CP.PHAR.228 | August 1, 2025 |
| Travoprost (iDose TR) (PDF) | CP.PHAR.672 | April 1, 2025 |
| Tremelimumab-actl (Imjudo) (PDF) | CP.PHAR.612 | June 1, 2025 |
| Treprostinil (Orenitram, Remodulin, Tyvaso) (PDF) | CP.PHAR.199 | November 1, 2025 |
| Triamcinolone ER Injection (Zilretta) (PDF) | CP.PHAR.371 | June 1, 2025 |
| Trigger Point Injections for Pain Management (PDF) | CP.MP.169 | September 1, 2025 |
| Triptorelin pamoate (Trelstar, Triptodur) (PDF) | CP.PHAR.175 | June 1, 2025 |
| Ublituximab-xiiy (Briumvi) (PDF) | CP.PHAR.621 | October 1, 2025 |
| Urinary Incontinence Devices and Treatments (PDF) | CP.MP.142 | May 1, 2025 |
| Ustekinumab (Stelara and biosimilars) (PDF) | CP.PHAR.264 | October 1, 2025 |
| Vagus Nerve Stimulation (PDF) | CP.MP.12 | September 1, 2025 |
| Valoctocogene Roxaparvovec (PDF) | CP.PHAR.466 | May 1, 2025 |
| Valrubicin (Valstar) (PDF) | CP.PHAR.439 | March 1, 2025 |
| Vedolizumab (Entyvio) (PDF) | CP.PHAR.265 | September 1, 2025 |
| Velaglucerase alfa (VPRIV) (PDF) | CP.PHAR.163 | October 1, 2025 |
| Velaglucerase alfa (VPRIV) (PDF) | CP.PHAR.163 | October 1, 2025 |
| Velmanase Alfa-tycv (Lamzede) (PDF) | CP.PHAR.601 | July 1, 2025 |
| Ventricular Assist Devices (PDF) | CP.MP.46 | February 1, 2025 |
| Verteporfin (Visudyne) (PDF) | CP.PHAR.187 | April 1, 2025 |
| Vestronidase Alfa-vjbk (Mepsevii) (PDF) | CP.PHAR.374 | July 1, 2025 |
| Viltolarsen (Viltepso) (PDF) | CP.PHAR.484 | April 1, 2025 |
| Voretigene neparvovec-rzyl (Luxturna) (PDF) | CP.PHAR.372 | April 1, 2025 |
| Vosoritide (Voxzogo) (PDF) | CP.PHAR.525 | April 1, 2025 |
| Vutrisiran (Amvuttra) (PDF) | CP.PHAR.550 | December 1, 2022 |
| Waiver Environmental Modifications Criteria (PDF) | ARTC.CC.25 | September 1, 2022 |
| Zanidatamab-hrii (Ziihera) (PDF) | CP.PHAR.709 | August 1, 2025 |
| Zavegepant (Zavzpret) (PDF) | CP.PHAR.630 | March 1, 2025 |
| Zenocutuzumab-zbco (Bizengri) (PDF) | CP.PHAR.713 | August 1, 2025 |
| Ziv-aflibercept (Zaltrap) (PDF) | CP.PHAR.325 | January 1, 2025 |
| Zoledronic Acid (PDF) | CP.PHAR.59 | June 1, 2025 |
| Zolbetuximab-clzb (Vyloy) (PDF) | CP.PHAR.705 | August 1, 2025 |